The FDA has accepted Cerecor’s (NASDAQ:CERC) IND application for CERC-802 and informed that the proposed study can begin immediately.
CERC-802, an oral formulation of D-mannose is currently in development for the treatment of Mannose Phosphate Isomerase (MPI) Deficiency, also known as MPI-CDG or CDG-1b.
The clinical program for CERC-802 will commence with a Phase I study in healthy volunteers. The goals will be to assess the single dose tolerability and pharmacokinetics of CERC-802.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.